Pathophysiology
Alpha-synuclein Lewy bodies accumulate in substantia nigra pars compacta; motor symptoms after >=60% dopamine loss. Genes: SNCA, LRRK2, GBA.
Sources: MDS Criteria (Mov Disord 2015;30:1591); AAN 2021 Levodopa
Presentation
TRAP: Tremor (4-6 Hz resting), Rigidity (cogwheel), Akinesia/bradykinesia, Postural instability. Non-motor: hyposmia, REM sleep behaviour disorder, constipation.
Diagnosis
Clinical MDS criteria; response to levodopa is supportive. DaT-SPECT differentiates from essential tremor when unclear.
Management
Levodopa/carbidopa (gold standard), dopamine agonists (pramipexole, ropinirole), MAO-B inhibitors (rasagiline). DBS of STN or GPi for motor fluctuations. Pimavanserin for PD psychosis - avoid haloperidol.







